What does MEDIFARM+ do?

MEDIFARM+ is a pharmacy in Brugge. Public Limited, started on 24 April 2015, 3 establishments.

What is the address of MEDIFARM+?

The registered office of MEDIFARM+ is located at Daverlostraat 110, 8310 Brugge.

Is MEDIFARM+ still active?

Yes. According to the CBE (30 October 2026) MEDIFARM+ is active, legal situation “Normale toestand”, started on 24 April 2015.

Is MEDIFARM+ registered on Peppol?

Yes, MEDIFARM+ is registered on the Peppol network with ID 0208:0629857424.

What is the enterprise number of MEDIFARM+?

The enterprise number of MEDIFARM+ is BE0629857424.

When was MEDIFARM+ founded?

MEDIFARM+ was founded on 24 April 2015.

Who are the directors of MEDIFARM+?

According to the 2025 annual accounts, the directors of MEDIFARM+ are: Likaver Invest NV, Nathalie Verschuere.

Is MEDIFARM+ a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 April 2015; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 3 establishments in the CBE.

How much profit did MEDIFARM+ make in 2025?

MEDIFARM+ posted a profit after taxes of € 136,111 in financial year 2025.

What is the revenue of MEDIFARM+?

As a small company, MEDIFARM+ is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 611,676.

How much does an employee at MEDIFARM+ earn?

The average wage cost per full-time employee at MEDIFARM+ was € 56,300 in 2025: staff costs of € 326,409 for 5.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does MEDIFARM+ have?

According to the 2025 annual accounts, MEDIFARM+ has 5.8 full-time equivalents (FTE).

MEDIFARM+ (Public Limited) - Brugge - BE0629857424

Dossier MEDIFARM+, printed on 30 October 2026 from databakkes.be/en/0629857424/medifarm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 58 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

MEDIFARM+ from Brugge, company number BE0629857424, closed financial year 2025 with a result of € 136,111 after tax. For that financial year MEDIFARM+ recorded a gross margin of € 611,676 and equity of € 255,409. Compared with financial year 2024, the result moved from € 190,109 to € 136,111. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 30, 2026.

What it is worth Growing

€ 255,409

▲ 9% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 136,111

▼ 28% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 232,316

▲ 66% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 116,000 paid out

85 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

5.8

▼ 0.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 326,409

▼ 23% vs 2024

€ 56,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 9,878

▼ 49% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 13 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.5 million

▼ 5% vs 2024

€ 115,316 is repaid this year. At this pace the long-term loan is gone in ≈ 13 years.

Owed to suppliers

€ 570,757

▲ 106% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 82,649

▲ 36% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 439,071 Gross margin 2022: € 439,071 First fiscal year in the series	€ 385,220 Gross margin 2023: € 385,220 ▼ 12% vs 2022 (€ 439,071) Unfavourable step	€ 775,204 Gross margin 2024: € 775,204 ▲ 101% vs 2023 (€ 385,220) Favourable step	€ 611,676 Gross margin 2025: € 611,676 ▼ 21% vs 2024 (€ 775,204) Unfavourable step	▼ 21%
Profit after taxes	€ 100,635 Profit after taxes 2022: € 100,635 First fiscal year in the series	€ 89,709 Profit after taxes 2023: € 89,709 ▼ 11% vs 2022 (€ 100,635) Unfavourable step	€ 190,109 Profit after taxes 2024: € 190,109 ▲ 112% vs 2023 (€ 89,709) Favourable step	€ 136,111 Profit after taxes 2025: € 136,111 ▼ 28% vs 2024 (€ 190,109) Unfavourable step	▼ 28%
Equity	€ 269,634 Equity 2022: € 269,634 First fiscal year in the series	€ 305,190 Equity 2023: € 305,190 ▲ 13% vs 2022 (€ 269,634) Favourable step	€ 235,299 Equity 2024: € 235,299 ▼ 23% vs 2023 (€ 305,190) Unfavourable step	€ 255,409 Equity 2025: € 255,409 ▲ 9% vs 2024 (€ 235,299) Favourable step	▲ 9%
Total debts	€ 2,187,708 Total debts 2022: € 2,187,708 First fiscal year in the series	€ 2,286,561 Total debts 2023: € 2,286,561 ▲ 5% vs 2022 (€ 2,187,708) Unfavourable step	€ 2,183,645 Total debts 2024: € 2,183,645 ▼ 5% vs 2023 (€ 2,286,561) Favourable step	€ 2,496,905 Total debts 2025: € 2,496,905 ▲ 14% vs 2024 (€ 2,183,645) Unfavourable step	▲ 14%
Cash	€ 138,392 Cash 2022: € 138,392 First fiscal year in the series	€ 144,062 Cash 2023: € 144,062 ▲ 4% vs 2022 (€ 138,392) Favourable step	€ 140,154 Cash 2024: € 140,154 ▼ 3% vs 2023 (€ 144,062) Unfavourable step	€ 232,316 Cash 2025: € 232,316 ▲ 66% vs 2024 (€ 140,154) Favourable step	▲ 66%
Land & buildings	-	-	€ 547,444 Land & buildings 2024: € 547,444 First fiscal year in the series	€ 540,630 Land & buildings 2025: € 540,630 ▼ 1% vs 2024 (€ 547,444) Unchanged	▼ 1%
Retained profit	€ 207,276 Retained profit 2022: € 207,276 First fiscal year in the series	€ 242,832 Retained profit 2023: € 242,832 ▲ 17% vs 2022 (€ 207,276) Favourable step	€ 172,941 Retained profit 2024: € 172,941 ▼ 29% vs 2023 (€ 242,832) Unfavourable step	€ 193,051 Retained profit 2025: € 193,051 ▲ 12% vs 2024 (€ 172,941) Favourable step	▲ 12%
Dividend	€ 54,153 Dividend 2022: € 54,153 First fiscal year in the series	€ 54,153 Dividend 2023: € 54,153 Unchanged (€ 54,153) Unchanged	€ 260,000 Dividend 2024: € 260,000 ▲ € 205,847 vs 2023 (€ 54,153) Unchanged	€ 116,000 Dividend 2025: € 116,000 ▼ 55% vs 2024 (€ 260,000) Unchanged	▼ 55%
Bank debt	€ 1,810,484 Bank debt 2022: € 1,810,484 First fiscal year in the series	€ 1,705,274 Bank debt 2023: € 1,705,274 ▼ 6% vs 2022 (€ 1,810,484) Favourable step	€ 1,586,286 Bank debt 2024: € 1,586,286 ▼ 7% vs 2023 (€ 1,705,274) Favourable step	€ 1,500,393 Bank debt 2025: € 1,500,393 ▼ 5% vs 2024 (€ 1,586,286) Favourable step	▼ 5%
Balance sheet total	€ 2,457,342 Balance sheet total 2022: € 2,457,342 First fiscal year in the series	€ 2,591,752 Balance sheet total 2023: € 2,591,752 ▲ 5% vs 2022 (€ 2,457,342) Unchanged	€ 2,418,944 Balance sheet total 2024: € 2,418,944 ▼ 7% vs 2023 (€ 2,591,752) Unchanged	€ 2,752,314 Balance sheet total 2025: € 2,752,314 ▲ 14% vs 2024 (€ 2,418,944) Unchanged	▲ 14%
Employees (FTE)	4.6 Employees (FTE) 2022: 4.6 First fiscal year in the series	4.5 Employees (FTE) 2023: 4.5 ▼ 0.1 vs 2022 (4.6) Unchanged	6.3 Employees (FTE) 2024: 6.3 ▲ 1.8 vs 2023 (4.5) Unchanged	5.8 Employees (FTE) 2025: 5.8 ▼ 0.5 vs 2024 (6.3) Unchanged	▼ 0.5

Key figures of MEDIFARM+, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to MEDIFARM+?

What happened at MEDIFARM+ in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 30, 2026 New annual accounts for financial year 2025: profit of € 136,111 (▼ 28% vs 2024). Source: NBB ↗
May 4, 2015 New establishment in Brugge. KBO
May 4, 2015 New establishment in Brugge. KBO
Apr 24, 2015 Start of the company according to the CBE. KBO
Feb 2, 1983 New establishment in Brugge. KBO

In short

From € 100,635 profit in 2022 to € 136,111 profit in 2025.

Paid € 47,560 in corporate taxes since 2022.

Best year ever: 2024, with € 190,109 profit.

On average € 105,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Likaver Invest NV Nathalie Verschuere

MEDIFARM+

Apotheek Van Overschelde

LIKAVER INVEST

Behind MEDIFARM+ are Likaver Invest NV and Nathalie Verschuere. Nathalie Verschuere is also behind Apotheek Van Overschelde and LIKAVER INVEST.

Directors

According to the 2025 annual accounts

Likaver Invest NV

Director · represented by Nathalie Verschuere

Nathalie Verschuere

Director

Also active at: Apotheek Van Overschelde, LIKAVER INVEST

Establishments

Establishment units

Physical locations of this company

Registered office

Daverlostraat 110

8310 Brugge

2.021.777.631

Wantestraat 152

8310 Brugge

Active since 2 February 1983

2.242.051.070

Astridlaan 242

8310 Brugge

Active since 4 May 2015

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

MEDIFARM

€ 15,745 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0629.857.424

VAT number

BE 0629.857.424

Registered office

Daverlostraat 110, 8310 Brugge

Names & denominations

MEDIFARM+

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

24 April 2015

Peppol

Active · Active since 22 Oct 2025

Activities · NACE

Detailhandel in farmaceutische producten

Overige detailhandel in voedingsmiddelen, neg

Detailhandel in cosmetica en toiletartikelen

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.

View on CBE Public ↗ Annual accounts (NBB) ↗

MEDIFARM+

Warning lights

Financials

What happened to MEDIFARM+?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions